We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

111 hedge funds and large institutions have $561M invested in CytomX Therapeutics in 2018 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 40 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

8,350% more call options, than puts

Call options by funds: $169K | Put options by funds: $2K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.14% less ownership

Funds ownership: 84.06% → 83.92% (-0.14%)

8% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 40

9% less funds holding

Funds holding: 122 → 111 (-11)

20% less capital invested

Capital invested by funds: $698M → $561M (-$137M)

38% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 26

Holders
111
Holders Change
-11
Holders Change %
-9.02%
% of All Funds
2.47%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
16
Increased
37
Reduced
40
Closed
26
Calls
$169K
Puts
$2K
Net Calls
+$167K
Net Calls Change
+$1.07M

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$31.9M
2
RI
RTW Investments
New York
+$13.5M
3
CAM
Cormorant Asset Management
Massachusetts
+$4.4M
4
PA
Perceptive Advisors
New York
+$3.71M
5
AG
Artal Group
Luxembourg
+$2.23M

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$15.6M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$12.2M
3
State Street
State Street
Massachusetts
-$6.55M
4
Franklin Resources
Franklin Resources
California
-$6.17M
5
CC
Casdin Capital
New York
-$3.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
WS
76
Wedbush Securities
California
$383K +$28.2K +1,900 +8%
Los Angeles Capital Management
77
Los Angeles Capital Management
California
$313K -$3.19K -215 -1%
VEA
78
Virtus ETF Advisers
New York
$308K +$23.2K +1,565 +8%
ProShare Advisors
79
ProShare Advisors
Maryland
$301K -$57K -3,840 -16%
AQR Capital Management
80
AQR Capital Management
Connecticut
$281K -$206K -13,871 -43%
MIM
81
MetLife Investment Management
New Jersey
$276K – – –
VOYA Investment Management
82
VOYA Investment Management
Georgia
$272K +$27.6K +1,862 +12%
SCA
83
Secor Capital Advisors
New York
$257K +$252K +17,017 New
State Board of Administration of Florida Retirement System
84
State Board of Administration of Florida Retirement System
Florida
$240K +$36.8K +2,478 +18%
MLICM
85
Metropolitan Life Insurance Company (MetLife)
New York
$204K +$8.34K +562 +4%
UBS AM
86
UBS AM
Illinois
$196K – – –
DekaBank Deutsche Girozentrale
87
DekaBank Deutsche Girozentrale
Germany
$178K -$38.6K -2,600 -18%
WT
88
Whittier Trust
California
$166K – – –
QSS
89
Quantitative Systematic Strategies
Florida
$165K +$162K +10,939 New
SAM
90
Sectoral Asset Management
Quebec, Canada
$152K – – –
BFM
91
Boothbay Fund Management
New York
$151K +$148K +10,000 New
Legal & General Group
92
Legal & General Group
United Kingdom
$126K +$19.4K +1,306 +19%
MWNA
93
Marshall Wace North America
New York
$84K +$82.9K +5,589 New
MCM
94
Manchester Capital Management
Vermont
$74K – – –
Canada Life
95
Canada Life
Manitoba, Canada
$72K – – –
AIP
96
Ameritas Investment Partners
Nebraska
$49K – – –
Zurich Cantonal Bank
97
Zurich Cantonal Bank
Switzerland
$37K – – –
Barclays
98
Barclays
United Kingdom
$26K -$232K -15,622 -90%
Fifth Third Bancorp
99
Fifth Third Bancorp
Ohio
$22K – – –
IUHSA
100
Itau Unibanco Holding S.A.
Brazil
$21K +$20.9K +1,406 New
2 3
4
5 6

CTMX Hedge Fund Activity: Q4 2018 in Review

111 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2018, worth a combined $561M — down 20% from $698M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of CTMX and 16 opened new positions — a net loss of 10 holders — while 40 trimmed existing stakes and 37 added.

The largest buyer was Wellington Management Group, adding an estimated $31.9M. The largest seller was Vanguard Group, cutting an estimated $15.6M.

  • 111 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2018, down from 122 in Q3 2018.
  • Funds reported $561M of CytomX Therapeutics stock for Q4 2018, down 20% quarter-over-quarter.
  • 16 funds opened new CytomX Therapeutics positions in Q4 2018 and 26 closed out, a net change of -10 holders.
  • The largest CytomX Therapeutics buyer in Q4 2018 was Wellington Management Group, an estimated $31.9M added.
  • The largest CytomX Therapeutics seller in Q4 2018 was Vanguard Group, an estimated $15.6M sold.

Based on aggregated 13F filings for Q4 2018.